

The transition from psoriasis to psoriatic arthritis and the early diagnosis of psoriatic arthritis are of considerable scientific and clinical interest. People typically have psoriatic skin disease for a decade or more before they begin to experience the joint involvement of psoriatic arthritis.

Understanding more about the natural history and trajectory of this disease will help in the future prevention of the transition from psoriasis to psoriatic arthritis. The early diagnosis of psoriatic arthritis is also of considerable scientific and clinical interest.

The new EULAR (The European Alliance of Associations for Rheumatology) points-to-consider¹ were developed by a multidisciplinary task force of 30 members from 13 European countries, with healthcare professionals from rheumatology and dermatology, as well as methodologists and patient research partners.

The work was completed in line with EULAR standardised operating procedures. All information included in the final paper, published in the June 2023 issue of the *Annals of the Rheumatic Diseases*, was based on two systematic literature reviews plus expert consensus.

Overall, five overarching principles and ten points-to-consider were formulated. The principles acknowledge that people with psoriasis may develop psoriatic arthritis at different times (or not at all) and highlight that there is a need for close collaboration between dermatologists and rheumatologists, although the rheumatologist has a key role in psoriatic arthritis diagnosis and management.

They also stress that being able to identify risk factors for psoriatic arthritis may influence therapy choices in people with psoriasis, especially since certain systemic treatments for psoriasis may reduce the risk of transition to psoriatic arthritis. The points-to-consider highlight arthralgia (joint pain) and abnormalities seen on ultrasound or MRI (magnetic resonance imaging) as key elements of sub-clinical psoriatic arthritis that can potentially be used as short-term predictors of who will go on to develop psoriatic arthritis.

eular

EUROPEAN ALLIANCE
OF ASSOCIATIONS
FOR RHEUMATOLOGY

This also makes these elements useful in designing clinical trials looking at psoriatic arthritis interception and prevention. Traditional risk factors for psoriatic arthritis development, such as psoriasis severity, obesity and nail involvement, may represent more long-term disease predictors. As such, these are felt to be less useful for short-term trials investigating the transition from psoriasis to psoriatic arthritis.

The task force also proposed some standard naming for three distinct stages in psoriatic arthritis development. Firstly, people with psoriasis at higher risk of psoriatic arthritis, then people with sub-clinical psoriatic arthritis, and then people with clinical psoriatic arthritis. This is important, as it has been shown in other inflammatory rheumatic musculoskeletal diseases that clinical onset is preceded by a pre-clinical phase where a person has arthralgia and immunological or imaging abnormalities, in the absence of a clinical diagnosis. The task force also proposed a definition for early psoriatic arthritis based on the development of joint swelling as a clinical outcome measure for trials of psoriatic arthritis.

EULAR hopes this publication will help to define the clinical and imaging features of people with psoriasis who should raise clinical suspicion for progression to psoriatic arthritis. They also hope it can be used to identify people who could benefit from a therapeutic intervention to delay or prevent psoriatic arthritis.

In the meantime, people with psoriasis should be informed about the risk of developing psoriatic arthritis and encouraged to report their symptoms to facilitate early psoriatic arthritis recognition.

In another study, published in *Arthritis & Rheumatology*, investigators developed and validated a tool called PRESTO² that identifies people with psoriasis who face an elevated risk of



arthritis. For example, PRESTO can be used to enrich prevention trials with at-risk populations. It can also identify patients with psoriasis who can benefit from early treatments, and it can serve as an educational tool for patients to increase awareness of psoriatic arthritis risk," said corresponding author Lihi Eder, MD, PhD, of Women's College Hospital and the University of Toronto in Canada. "Ultimately, we hope that these efforts will improve the lives of people living with psoriatic disease."

Comment:

In these two recent pieces of work, a clear message is that early detection of psoriatic arthritis is needed, along with monitoring people with psoriasis, so action can be taken to avoid the potential issues that arise once psoriatic arthritis has become obvious.

developing psoriatic arthritis and may therefore benefit from preventive therapies.

Among 635 people with psoriasis followed in the University of Toronto psoriasis cohort, 51 and 71 developed psoriatic arthritis during one-year and five-year follow-up periods, respectively.

The risk of developing psoriatic arthritis within one year was higher in people of younger age, male sex, family history of psoriasis, back stiffness, nail pitting (dents, ridges, and holes in the nails), joint stiffness, use of biologic medications, poor health or pain severity.

The risk of developing psoriatic arthritis within five years was higher in people with morning stiffness, psoriatic nail lesion, psoriasis severity, fatigue, pain, or use of systemic non-biologic medication or phototherapy.

Taking these data into account, PRESTO uses a mathematical model to estimate an individual's risk of developing psoriatic arthritis. The PRESTO calculator is available online.

"The PRESTO tool could serve future efforts to reduce the progression from psoriasis to psoriatic

References:

1. Zabotti A, et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. *Ann Rheum Dis* 2023; 0:1–9. doi:10.1136/ard-2023-224148.
2. Eder L, et al. Derivation of a Multivariable Psoriatic Arthritis Risk Estimation Tool (PRESTO): A Step Towards Prevention. *Arthritis & Rheumatology*. First published: 09 August 2023.

About EULAR:

The European Alliance of Associations for Rheumatology, EULAR, is the non-profit organisation that represents people with rheumatic and musculoskeletal diseases (RMDs), health professionals in rheumatology (HPR), rheumatologists and scientific societies of rheumatology of all the European nations.